Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

Have you been paying attention to current events recently? See how many of these 10 questions you can get right. Compiled by Jeremy Engle and Michael Gonchar Should There Be an Age Minimum for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals ... inadequate acid suppression with current drugs, and complex treatment regimens, according ...

Between 700,000 and around one million accounts have been switched every year since 2014, according to data from the Current Account Switch Service (CASS), which helps facilitate the process.